OncoMatch/Clinical Trials/NCT04570943
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Is NCT04570943 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Gabrinox for locally advanced pancreatic adenocarcinoma.
Treatment: Gabrinox — The aim of this study is to demonstrate the efficacy of intensified and sequential chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in patients with locally advanced pancreatic adenocarcinoma. The study will also demonstrate the feasibility of combining this intensified chemotherapy with MRI-guided stereotactic radiotherapy in non-progressive patients after the chemotherapy by Gabrinox regimen.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Excluded: UGT1A1 *28
homozygous Uridine DiPhosphate Glucuronosyl Transferase 1 A1 (UGT1A1 * 28)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Any previous treatment for pancreatic cancer (e.g. chemotherapy, radiotherapy, surgery, targeted therapy, experimental therapy)
Cannot have received: radiotherapy
Any previous treatment for pancreatic cancer (e.g. chemotherapy, radiotherapy, surgery, targeted therapy, experimental therapy)
Cannot have received: surgery
Any previous treatment for pancreatic cancer (e.g. chemotherapy, radiotherapy, surgery, targeted therapy, experimental therapy)
Cannot have received: targeted therapy
Any previous treatment for pancreatic cancer (e.g. chemotherapy, radiotherapy, surgery, targeted therapy, experimental therapy)
Cannot have received: experimental therapy
Any previous treatment for pancreatic cancer (e.g. chemotherapy, radiotherapy, surgery, targeted therapy, experimental therapy)
Cannot have received: radiotherapy
Prior radiotherapy likely to overlap with the planned study radiotherapy area (e.g. previous abdominal irradiation).
Lab requirements
Blood counts
Neutrophils ≥ 2 000/mm3; Platelets ≥ 100 000/mm3; Hemoglobin ≥ 9 g/dl
Kidney function
Creatininaemia within reference limits, or calculated clearance ≥50 ml/min (CKDEPI formula)
Liver function
AST and ALT ≤ 2.5 x ULN; total bilirubin ≤ 1.5 x ULN (special conditions for patients with metallic biliary prosthesis)
Hematological assessment within 14 days before inclusion, defined by: Neutrophils ≥ 2 000/mm3; Platelets ≥ 100 000/mm3; Hemoglobin ≥ 9 g/dl. Liver function (within 14 days before inclusion) defined by: AST and ALT ≤ 2.5 x ULN; total bilirubin ≤ 1.5 x ULN. Creatininaemia within the reference limits, or calculated clearance ≥50 ml/min for patients with a serum creatinine value above or below the reference values (CKDEPI formula).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04570943 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with UGT1A1 alterations eligible?
No. UGT1A1 *28 is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages